Literature DB >> 33320287

miR-573 suppresses pancreatic cancer cell proliferation, migration, and invasion through targeting TSPAN1.

Lei Wang1, Peng Gao2, Ping Yuan3, Pengcheng Zhou4, Haowen Fan5, Xida Lin5, Xiaoyu Yuan6, Mingyan Zhu1, Xiangjun Fan1, Yuhua Lu7, Zhiwei Wang8.   

Abstract

PURPOSE: To explore whether miR-573 can suppress pancreatic cancer cell proliferation, migration, and invasion by targeting TSPAN1.
METHODS: The expression of miR-573 and TSPAN1 in pancreatic cancer tissues and cells lines was analyzed using RT-qPCR. The human pancreatic cancer cell line PANC‑1 was transfected with miR-573 mimic, pcDNA3.1-TSPAN1, or genOFFTM st-h-TSPAN1. The effects of miR-573 and TSPAN1 on cell proliferation, colony formation, migration, and invasion were analyzed by CCK‑8, colony formation, transwell migration, and invasion assay, respectively. Target genes of miR-573 were screened using bioinformatics tools and confirmed by dual-luciferase reporter assay and real-time PCR. The effects of miR-573 in vivo were observed using tumor xenografts.
RESULTS: We found that miR-573 is downregulated and TSPAN1 is upregulated in pancreatic cancer tissues and cells lines. Function assays demonstrated that overexpression of miR-573 inhibited cell proliferation, colony formation, migration, and invasion of pancreatic cancer cells, as well as suppressing tumor growth in vivo. Target genes of miR-573 were predicted using bioinformatics tools and confirmed by dual-luciferase reporter assay and RT-qPCR or western blotting. Downregulation of TSPAN1 also inhibited cell proliferation, colony formation, migration, and invasion of pancreatic cancer cells. Furthermore, overexpression of TSPAN1 attenuated miR-573-induced inhibition of pancreatic cancer cell proliferation and migration.
CONCLUSION: Our findings indicated that miR-573 suppresses pancreatic cancer cell proliferation, migration, and invasion through targeting TSPAN1. TSPAN1 targeted by miR-573 might be a potential therapeutic target for clinical treatment of pancreatic cancer.

Entities:  

Keywords:  Invasion; Migration; Pancreatic cancer; Proliferation; TSPAN1; miR-573

Year:  2020        PMID: 33320287     DOI: 10.1007/s00066-020-01728-3

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  20 in total

1.  Long non-coding RNA TTN-AS1 promotes cell growth and metastasis in cervical cancer via miR-573/E2F3.

Authors:  Ping Chen; Rui Wang; Qingfen Yue; Mengmeng Hao
Journal:  Biochem Biophys Res Commun       Date:  2018-08-19       Impact factor: 3.575

2.  Cancer statistics, 2020.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2020-01-08       Impact factor: 508.702

3.  TSPAN1 functions as an oncogene in gastric cancer and is downregulated by miR-573.

Authors:  Zhengmao Lu; Tianhang Luo; Mingming Nie; Tao Pang; Xin Zhang; Xiaojun Shen; Liye Ma; Jianwei Bi; Guo Wei; Guoen Fang; Xuchao Xue
Journal:  FEBS Lett       Date:  2015-06-06       Impact factor: 4.124

4.  Integrating high-throughput microRNA and mRNA expression data to identify risk mRNA signature for pancreatic cancer prognosis.

Authors:  Ping Wang; Weidong Li; Bo Zhai; Xian Jiang; Hongchi Jiang; Chunlong Zhang; Xueying Sun
Journal:  J Cell Biochem       Date:  2019-12-30       Impact factor: 4.429

5.  Long non-coding RNA FLVCR1-AS1 contributes to the proliferation and invasion of lung cancer by sponging miR-573 to upregulate the expression of E2F transcription factor 3.

Authors:  Xinyuan Gao; Shasha Zhao; Xiaohua Yang; Shuzhi Zang; Xiaomei Yuan
Journal:  Biochem Biophys Res Commun       Date:  2018-10-09       Impact factor: 3.575

6.  Annual Report to the Nation on the Status of Cancer, part I: National cancer statistics.

Authors:  Kathleen A Cronin; Andrew J Lake; Susan Scott; Recinda L Sherman; Anne-Michelle Noone; Nadia Howlader; S Jane Henley; Robert N Anderson; Albert U Firth; Jiemin Ma; Betsy A Kohler; Ahmedin Jemal
Journal:  Cancer       Date:  2018-05-22       Impact factor: 6.860

7.  Development of microRNA-based therapy for pancreatic cancer.

Authors:  Andrew Fesler; Jingfang Ju
Journal:  J Pancreatol       Date:  2019-12

8.  MiR-573 inhibits prostate cancer metastasis by regulating epithelial-mesenchymal transition.

Authors:  Lin Wang; Guanhua Song; Weiwei Tan; Mei Qi; Lili Zhang; Jonathan Chan; Jindan Yu; Jinxiang Han; Bo Han
Journal:  Oncotarget       Date:  2015-11-03

Review 9.  MicroRNAs in Pancreatic Cancer: biomarkers, prognostic, and therapeutic modulators.

Authors:  Afra Z Daoud; Eoghan J Mulholland; Grace Cole; Helen O McCarthy
Journal:  BMC Cancer       Date:  2019-11-21       Impact factor: 4.430

10.  Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods.

Authors:  J Ferlay; M Colombet; I Soerjomataram; C Mathers; D M Parkin; M Piñeros; A Znaor; F Bray
Journal:  Int J Cancer       Date:  2018-12-06       Impact factor: 7.396

View more
  5 in total

1.  MicroRNA-573 inhibits cell proliferation, migration and invasion and is downregulated by PICSAR in cutaneous squamous cell carcinoma.

Authors:  Yanhua Wang; Shengjian Tang; Jianping Lv
Journal:  Bosn J Basic Med Sci       Date:  2022-04-01       Impact factor: 3.759

2.  LINC00511/hsa-miR-573 axis-mediated high expression of Gasdermin C associates with dismal prognosis and tumor immune infiltration of breast cancer.

Authors:  Kai Sun; Jing-Zhang Li; Zhan-Xiong Luo; Ri-Xin Chen
Journal:  Sci Rep       Date:  2022-08-30       Impact factor: 4.996

Review 3.  Research progress on microRNAs as molecular markers in pancreatic cancer: a narrative review.

Authors:  Rui-Biao Fu; Xi Chen; Yan Chen; Qing-Huang Ye; Bin Yang; Qian Shao; Jin-Hui Zhu
Journal:  J Gastrointest Oncol       Date:  2022-08

Review 4.  Tetraspanins as Potential Modulators of Glutamatergic Synaptic Function.

Authors:  Amina Becic; Jennifer Leifeld; Javeria Shaukat; Michael Hollmann
Journal:  Front Mol Neurosci       Date:  2022-01-03       Impact factor: 5.639

Review 5.  Pre-Clinical and Clinical Applications of Small Interfering RNAs (siRNA) and Co-Delivery Systems for Pancreatic Cancer Therapy.

Authors:  Sepideh Mirzaei; Mohammad Hossein Gholami; Hui Li Ang; Farid Hashemi; Ali Zarrabi; Amirhossein Zabolian; Kiavash Hushmandi; Masoud Delfi; Haroon Khan; Milad Ashrafizadeh; Gautam Sethi; Alan Prem Kumar
Journal:  Cells       Date:  2021-11-29       Impact factor: 6.600

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.